Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.

Launched by ASTRAZENECA · Apr 17, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a lung cancer screening program that uses a special type of imaging called low-dose tomography, along with tests that measure certain substances in the body (metabolomic evaluation). The goal is to see how effective this screening program is for people who smoke or have smoked in the past, particularly in a public health setting. This study is currently recruiting participants who are between 45 and 74 years old, have a significant smoking history, and have never been part of a lung cancer screening program before.

To be eligible, participants should have smoked at least 30 pack-years (which means if you smoked one pack a day for 30 years) or be a former smoker who quit less than 15 years ago. However, people with serious health issues that could affect their life expectancy or those who have had certain past conditions, like tuberculosis or other cancers, are not eligible. If you join the study, you can expect to undergo low-dose chest imaging, which is a less intense form of a CT scan, to help detect any early signs of lung cancer. This trial is important because early detection can lead to better treatment options and outcomes for lung cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 45 and 74 years old; Smoker with a smoking history of at least 30 pack-years or former smoker who has quit smoking for less than 15 years; Never having participated in a lung cancer screening program; Signing of the free and informed consent form.
• Exclusion Criteria:
• • Patients with chronic diseases (cardiovascular, pulmonary, hepatic, renal or metabolic) at an advanced stage that limit life expectancy or make it impossible to perform a curative surgical procedure; Patients being treated for tuberculosis or other granulomatous diseases; Patients diagnosed with previous neoplasm(s) that could develop lung metastases; Pregnant women; Patients who, for some reason, are unable to undergo low-dose chest computed tomography; Patients previously submitted to thoracic radiotherapy.